Abstract 1377P
Background
EGFR exon 20 insertion mutations (EGFRex20ins) can be classified as near-loop and far-loop based on their location. The underlying structural difference between near- vs. far-loop EGFRex20ins and its impact on various other novel EGFR TKIs response are not well understood.
Methods
We assessed in vitro activity of multiple EGFR TKIs against a panel of BaF3 cells expressing EGFRex20ins mutations. Molecular Dynamics (MD) modeling of near- vs. far-loop EGFRex20ins, with and without binding of EGFR TKIs was performed. Clinical responses (tumor size reduction and progression free survival) were analyzed by near- vs. far-loop insertion location in ZENITH20 and EXCLAIM trials.
Results
In vitro testing with different EGFRex20ins indicated a favorable IC50 for afatinib, CLN-081, and poziotinib in near-loop (A767-P772) versus far-loop (H773-R776) insertions, whereas mobocertinib had similar IC50 values in near- and far-loop insertions. MD modeling using free-energy calculations indicated that wildtype EGFR displayed distinct inactive and active states with a relatively high transitional energy barrier. In comparison, the near-loop (S768insSVD) exhibited multiple states separated by shallow barriers whereas the far-loop (H773insNPH) was conformationally more rigid. The differential p-loop orientation change in near- vs. far-loop insertions played an active role in TKI binding, stabilization, and selectivity. Clinical data supported the in vitro differential impact of insertion location. In the ZENITH20 trial (n=82), in pre-treated EGFRex20ins lung cancer patients, poziotinib had superior activity in near-loop than far-loop tumors both on tumor size reduction (-25.9% vs. -9.8%, p=0.0014) and PFS (11.1 vs. 3.5 months, Log Rank p=0.016). In the EXCLAIM trial platinum-pretreated patients (n=76), mobocertinib demonstrated robust activity in both groups as assessed by tumor size reduction (near -38.5% vs. far -34.1%, p=0.59) and PFS (12.0 vs. 13.0, Log Rank p=0.99).
Conclusions
Preclinical and clinical data indicated that near- vs far-loop EGFRex20 insertions differentially impact sensitivity to individual TKIs. Thus, knowledge of insertion location may allow for more effectively tailored TKI therapy.
Clinical trial identification
ZENITH20: NCT03318939; EXCLAIM: NCT02716116.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Damon Runyon Foundation.
Disclosure
X. Le: Financial Interests, Personal, Advisory Board: AstraZeneca, Merck KGaA, Spectrum Pharmaceutics, Novartis, Boehringer Ingelheim, Eli Lilly, Hengrui, Janssen, Blueprint, Daiichi Sankyo, Regeneron, ArriVent, Abion, Pinetree Therapeutics, AbbVie; Financial Interests, Institutional, Coordinating PI: Eli Lilly, EMD Serono, Regeneron, Janssen; Financial Interests, Institutional, Research Grant: Arrivent; Financial Interests, Institutional, Funding: Teligene. J.P. Robichaux: Financial Interests, Personal, Affiliate: AstraZeneca. G. Bhat, F. Lebel: Financial Interests, Personal, Affiliate: Spectrum. S. Vincent, V. Bunn, Z. Su: Financial Interests, Personal, Affiliate: Takeda. J. Heymach: Financial Interests, Personal, Advisory Board: Genentech, Mirati Therapeutics, Eli Lilly & Co., Janssen Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Regeneron, Takeda Pharmaceuticals, BerGenBio, Jazz Pharmaceuticals, Curio Science, Novartis, AstraZeneca, BioAlta, Sanofi, Spectrum Pharmaceuticals, GSK, Spectrum; Financial Interests, Personal, Full or part-time Employment: MD Anderson Cancer Center; Financial Interests, Institutional, Other, International PI for clinical trials: AstraZeneca; Financial Interests, Institutional, Other, International PI for two clinical trials: Boehringer Ingelheim; Financial Interests, Personal and Institutional, Other, Developed a drug: Spectrum; Financial Interests, Institutional, Coordinating PI: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20